7 Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: Experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults

Patte, Catherine; Michon, Jean; Frappaz, Didier; Leverger, G; Rubie, H; Soussain, Carole; Jl, Pico

doi:10.1016/s0950-3536(05)80206-9

Cited by 73 publications

(33 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 With the current chemotherapy regimens, the overall cure rates are approximately 90% in children and 50% to 60% in adults. [12][13][14][15] However, patients with high-stage disease continue to have a less favorable prognosis, with cure rates of 80% to 85% in children 15 and 40% to 50% in adults 16 There are no known biological tumor features that reliably predict the behavior of BL. In addition, it is not entirely clear if the difference in outcome between children and adults is a result of a relatively poor tolerance to treatment in the latter or if it is at least partially attributable to differences in tumor biology.…”

mentioning

confidence: 99%

Secondary chromosomal abnormalities predict outcome in pediatric and adult high‐stage Burkitt lymphoma

Onciu

Schlette

Zhou

et al. 2006

Cancer

View full text Add to dashboard Cite

Recent studies suggest that the hypodigms representing the two earliest Australopithecus (Au. anamensis and Au. afarensis) form an ancestor‐descendant lineage. Understanding the details of this possible transition is important comparative evidence for assessing the likelihood of other examples of ancestor‐descendant lineages within the hominin clade. To this end we have analyzed crown and cusp base areas of high resolution replicas of the mandibular molars of Au. anamensis (Allia Bay and Kanapoi sites) and those of Au. afarensis (Hadar, Laetoli, and Maka). We found no statistically significant differences in crown areas between these hypodigms although the mean of M1 crowns was smaller in Au. anamensis, being the smallest of any Australopithecus species sampled to date. Intraspecies comparison of the areas of mesial cusps for each molar type using Wilcoxon signed rank test showed no differences for Au. anamensis. Significant differences were found between the protoconid and metaconid of Au. afarensis M2s and M3s. Furthermore, the area formed by the posterior cusps as a whole relative to the anterior cusps showed significant differences in Au. afarensis M1s and in Au. anamensis M2s but no differences were noted for M3s of either taxon. Developmental information derived from microstructural details in enamel shows that M1 crown formation in Au. anamensis is similar to Pan and shorter than in H. sapiens. Taken together, these data suggests that the overall trend in the Au. anamensis‐Au. afarensis transition may have involved a moderate increase in M1 crown areas with relative expansion of distal cusps. Am J Phys Anthropol , 2012. © 2012 Wiley Periodicals, Inc.

show abstract

mentioning

confidence: 99%

Secondary chromosomal abnormalities predict outcome in pediatric and adult high‐stage Burkitt lymphoma

Onciu

Schlette

Zhou

et al. 2006

Cancer

View full text Add to dashboard Cite

show abstract

“…Moreover, these results could not be reproduced by the SFOP group (Valteau-Coinet, personal communication). Thus the dramatic improvements described in high grade lymphoma by increasing the dose of known drugs during induction therapy cannot be translated to metastatic neuroblastoma (Patte et al, 1994). It thus seems unlikely that further intensification of induction may result in major improvement of remission rate, as it did not change between three successive cohorts, but this issue is addressed in the recently completed ENSG5 study which compares standard dose of OPEC/OJEC with the rapid COJEC regimen (Pinkerton et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis

et al. 2002

View full text Add to dashboard Cite

The Lyon-Marseille-Curie-Est (LMCE) of France cooperative group has previously reported successive series of unselected stage four children older than 1 year at diagnosis with metastatic neuroblastoma (LMCE 1 and 3). The goal of LMCE 5 study was to increase progression free survival rate as compared to LMCE 1 and 3. Based on improvements reported with post induction chemotherapy, the LMCE 5 used post induction for all children, but omitted total body irradiation and immunomagnetic purging in megatherapy regimen for all children. Twenty-five sequentially diagnosed children received an induction regimen which compared with previous induction included an increased dose of etoposide and cyclophosphamide, delivered similar dose of cisplatinum, and deleted doxorubicin and vincristin. After surgery treatment was stratified based on response and eligible children received etoposide carboplatin (LMCE 5A : n=10)+doxorubicin (LMCE 5B -C n=13) followed by megatherapy (melphalan without total body irradiation and unpurged peripheral blood stem cell rescue). The increase in drug doses during induction did not improve remission rate. The progression free survival at 6 years is 8%. It is significantly worse than LMCE 3, and equivalent to LMCE 1 study though toxic death rate has decreased with increasing experience. Failure to improve the response rate during induction and reducing the megatherapy regimen may be the main factors in this disappointing result. Modified strategies for induction, non toxic alternative to total body irradiation, and post megatherapy regimen should be developed.

show abstract

“…Details of the specific protocols have been provided previously. 4,[14][15][16][17][18][19][20][21][22][23] Schedules of protocol trials are summarized in Figure 1. Adjustments in the post-remission chemotherapy program were made to the dose or timing of consolidation therapy only under exceptional circumstances.…”

Section: Treatmentmentioning

confidence: 99%

“…The classical improved outcome in L3 ALL was not confirmed in our study because of the lack of patients receiving specifically designed regimens. 23 Intensification of post-remission treatment is likely to contribute to improvement of treatment outcome in younger patients. This seems mainly due more to the development of SCT than to the intensification of consolidation chemotherapy.…”

Section: Figurementioning

confidence: 99%

Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period

et al. 2001

View full text Add to dashboard Cite

Although the prospect of long-term leukemia-free survival (LFS) after treatment for adult acute lymphoblastic leukemia (ALL) is widely accepted, few studies have reported long-term survival data. Three hundred and seventy-eight ALL patients, referred to our hospital from 1978 to 1999, were reviewed for long-term follow-up data. The analysis included data on 351 patients treated by standard chemotherapy according to 11 different successive and/or concomitant regimens. Complete remission (CR) was achieved in 299 patients (79%). Initial performance status, LDH level, immunophenotype, age, and risk group (defined according to Hoelzer's criteria) at diagnosis were of significant prognostic value for CR achievement. Median leukemia-free survival (LFS) was 14 months with a 3-year, a 5-year, and an 8-year LFS at 30%, 26%, and 24%, respectively. LFS was better in T cell lineage ALL than in B cell lineage ALL (P ‫؍‬ 0.05). Younger age was also a favorable prognostic factor for LFS (P ‫؍‬ 0.001). Philadelphia-positive (Ph+) ALL displayed a poor outcome since median LFS was 7 months with only 13% of survival at 3 years. Median overall survival (OS) of the entire cohort was 18 months with a 3-year, a 5-year, and an 8-year OS at 32%, 24%, and 22% respectively. Favorable prognostic factors for OS were younger age (P Ͻ 0.0001), and T cell lineage ALL (P ‫؍‬ 0.001). Among non-T cell lineage ALL, standard-risk ALL confirmed a significant better outcome than high-risk ALL (P ‫؍‬ 0.0003). It was apparent from this analysis that hazard rates for death and relapse were greatest in the first year, decreased substantially between years 1 and 2, then decrease further between years 2 and 3. Rates of death and relapse were quite low after 3-4 years. All patients relapsing after 3 years of CR were B or non-B non-T cell lineage ALL. Long-term survivors (LTS), defined as survival in CR у3 years, represented 23% of evaluable patients. Eighty-three patients remain alive in initial CR at Ͼ3 years, while only three were LTS after a second CR. Overall, no significant improvement was shown in terms of CR achievement and survival duration over the years. However, regarding survival, a significant improvement was demonstrated in T cell lineage ALL (P ‫؍‬ 0.03). Furthermore, patients (aged less than 50 years) transplanted while in first CR did significantly better than those receiving only chemotherapy as post-remission therapy (P Ͻ 0.0001). The 3-year OS, after allogeneic transplantation in first CR, was 74% in T cell lineage ALL, while it was less than 50% in B cell lineage ALL. This single center study on a large cohort of ALL patients reflects the degree to which ALL treatment remains unsuccessful in adults. Only T cell lineage ALL outcomes have improved over the years. The results suggest a time (3 years) at which it becomes reasonable to speak of potential cure, provided the patient is in CR. Leukemia (2001) 15, 1811-1822.

show abstract

7 Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: Experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults

Cited by 73 publications

References 15 publications

Secondary chromosomal abnormalities predict outcome in pediatric and adult high‐stage Burkitt lymphoma

Secondary chromosomal abnormalities predict outcome in pediatric and adult high‐stage Burkitt lymphoma

The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis

Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period

Contact Info

Product

Resources

About